A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 250
- Population
- ALL · 50 Years
- Duration
- 2025-11-27 to 2028-11-15
- Intervention
- Susvimo PDS Implant; Ranibizumab
- Comparator
- Not reported
- Outcomes measured
- Change From Baseline in Best Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 68 and 72, as Assessed Using the…; Change From Baseline in BCVA Score Over Time — From baseline up to Week 72; Percentage of Participants Who Lose ≤ 15, ≤ 10, ≤ 5, or Gain ≥ 0 Letters in BCVA Score From Baseline Over Time — From b…; Change From Baseline in Center Point Thickness (CPT) — From baseline up to Week 72; Change From Baseline in Central Subfield Thickness (CST) — From baseline up to Week 72; Proportion of Participants Who do not Undergo Supplemental Treatment With IVT Ranibizumab Before Each Refill-exchange P…; Number of Supplemental Treatments Participants Received in Each Refill Cycle — Up to Week 72; Frequency of Study Visits in Each Refill Cycle — Up to Week 72; Proportion of Participants Who Report Preferring PDS Compared With IVT Ranibizumab Treatment as Measured by the PDS Pat…; Proportion of Participants With Bilateral Disease Who Report Preferring PDS Compared With IVT Ranibizumab Treatment Mea…; Number of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs) — Up to approximately 19 months; Number of Participants With Adverse Events of Special Interests (AESIs) and their Severity, Including Ocular AESIs — Up…; Number of Participants With Ocular AESIs and Severity of Ocular AESIs During the Post-operative and Follow-up Period —…; Number of Participants With Adverse Device Effects (ADEs) and Severity of ADEs With PDS — Up to approximately 19 months; Number of Participants With Anticipated Serious Adverse Device Effects (ASADEs) and Severity of ASADEs With PDS — Up to…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.